Heger, Monica
January 2010
Discover;Jan/Feb2010, Vol. 31 Issue 1, p23
The article discusses the various U.S. stem cell studies being conducted since the ban on federal funding for stem cell research was overturned by U.S. President Barack Obama. Topics include an overview of the first clinical trial by the U.S. biotechnology company Geron using embryonic stem cells (ESCs) to treat paralysis, a University of Wisconsin study using skin fibroblasts to create ESCs, and an international pilot study to treat X-linked adrenoleukodystrophy (ALD).


Related Articles

  • Time to lift embryo research ban.  // Nature;11/12/1998, Vol. 396 Issue 6707, p97 

    Calls for a change in United States law regarding embryo research. Society's ability to regulate science; Advances in the culture of human embryonic stem cells; US ban on embryo research using federal funds; Lack of regulation for private sector; Geron, the company involved in embryo stem cell...

  • Stem Cell Diversification. Hobson, Katherine // U.S. News & World Report;Aug2009, Vol. 146 Issue 7, p31 

    The article examines the decision of U.S. President Barack Obama to remove government policy that had restricted the use of embryonic stem cells in medical applications. While much progress has been made in the research of adult stem cells, embryonic cells still hold the most promise for...

  • STEP FOR STEM CELLS. Park, Alice // Time;8/16/2010, Vol. 176 Issue 7, p15 

    The article reports that a human trial of an embryonic stem cell treatment for spinal cord injury has been approved by the U.S. Food and Drug Administration (FDA).

  • Should US fund embryonic-cell research? Belsie, Laurent // Christian Science Monitor;3/13/2001, Vol. 93 Issue 74, p2 

    Discusses controversy over the funding of embryonic stem cell research in the United States, as opponents claim it will violate the dignity of life and advocates hope it will cure diseases.

  • The stem-cell research debate.  // Christian Science Monitor;8/2/2001, Vol. 93 Issue 174, p19 

    Comments on the debate in the United States surrounding the question of whether stem-cell research should be federally funded, and relates this topic to the idea that promises of cure and life may be traced back to God.

  • ESC research cannot be ignored. Singh, Nandita // BioSpectrum;Jan2012, Vol. 10 Issue 1, p100 

    The author comments on the issues concerning embryonic stem cell (ESC) research in India. She highlights the decision of California-based Geron Corp. to exit in the market for ESC research to focus on other projects. She emphasizes the role of the government to impose policies to provide a clear...

  • Stem cell revival. Coghlan, Andy // New Scientist;10/27/2012, Vol. 216 Issue 2888, p4 

    The article reports on attempts to resume a human embryonic stem cells (hESCs) clinical trial program cancelled in 2011 by the biotechnology company Geron, noting that former Geron officials and the biotechnology firm BioTime have placed a bid for the stem cell assets of the original program.

  • "CIRM Awards $25 Mln To Support Spinal-Cord Injury Trial, $37.7 Mln for Basic Stem-Cell Science".  // Biomedical Market Newsletter;5/9/2011, p143 

    The article reports that the Governing Board of the California Institute for Regenerative Medicine (CIRM), the State Stem Cell Agency, has approved a grant worth 25 million dollars to support the first U.S. Food & Drug Administration (FDA)-approved clinical trial based on cells derived from...

  • Oncogene's Secret Growth Formula.  // BioWorld Today;5/3/2010, Vol. 21 Issue 84, Special section p2 

    The article discusses research on the transcription control mechanism in embryonic stem cells, published in the April 30, 2010 issue of "Cell."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics